Denosumab Solution For Injection

Denosumab is a human monoclonal antibody that inhibits RANK ligand (RANKL), a key regulator of osteoclast activity, thereby reducing bone resorption and increasing bone density. It is used primarily for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of giant cell tumor of bone. It is marketed under brand names like Prolia (for osteoporosis) and Xgeva (for oncology-related indications).